Basal Cell Carcinoma Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Global Basal Cell Carcinoma Market is segmented by treatment type (surgery, medication, and others), end-user (hospitals, specialty clinics, and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Basal Cell Carcinoma Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Basal Cell Carcinoma Treatment Market Size

Basal Cell Carcinoma Treatment Market  Summary
Study Period 2021 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 9.30 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Basal Cell Carcinoma Treatment Market  Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Basal Cell Carcinoma Treatment Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Basal Cell Carcinoma Treatment Market Analysis

The Basal Cell Carcinoma Treatment Market is expected to register a CAGR of 9.3% during the forecast period.

The studied market was adversely impacted by the pandemic, and several research studies have provided insights into the direct effect of the outbreak on various diagnostic and surgical procedures related to cancer. The COVID-19 pandemic resulted in a sharp decline in non-urgent medical visits, according to a research article published in the National Library of Medicine in March 2021. Delayed appointments led to serious health consequences, such as the prolonged diagnosis of melanoma and other skin malignancies. As a result, there was a sharp decrease in all skin biopsies (15% of what was predicted), keratinocyte carcinoma (KC) biopsies (18%), and melanoma biopsies (27%). Thus, the market was unfavourably impacted by the outbreak in its initial phase. However, as per the analysis, initiatives undertaken by key market players, such as product approvals and developments, are augmenting market growth in the post-pandemic phase. For instance, in February 2021, the USFDA approved the intravenous immunotherapy medication, cemiplimab-rwlc (Libtayo), for the treatment of patients with certain forms of advanced basal cell carcinoma. Thus, with such approvals, the market is expected to grow during the forecast period.

The major factors attributing to the growth of the market are the increasing prevalence of skin malignancies, a rise in various environmental factors that lead to more UV exposure, and an increasing geriatric population that is more susceptible to skin diseases. According to a March 2022 article published by WCRFI, there are two primary forms of skin cancer, namely melanoma, and non-melanoma. Squamous cell carcinoma and basal cell carcinoma are the most typical non-melanoma cancers. The 17th most prevalent cancer worldwide is cutaneous melanoma. In terms of prevalence, it ranks 15th among cancers in women and 13th among cancers in men. In 2020, there were more than 150,000 new cases of cutaneous melanoma. Similarly, according to an article published by the American Academy of Dermatology Association in April 2022, skin cancer is the most prevalent type of cancer among Americans. According to current projections, one in five Americans may have skin cancer at some point in their lives. In the United States, an estimated 9,500 people receive a skin cancer diagnosis each day. More than 3 million Americans are thought to be affected annually by nonmelanoma skin cancer (NMSC), which includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Thus, the increasing prevalence of skin cancer is expected to boost market demand for treatments, in turn bolstering the market's growth.

Further, growing R&D activities related to basal cell carcinoma treatment are projected to propel the market's growth. For instance, at the American Society for Dermatologic Surgery (ASDS) Annual Meeting held in October 2022, the research study by Pulse Biosciences demonstrated that the CellFX procedure is effective for low-risk superficial and nodular basal cell carcinoma lesion clearance using Nano-Pulse Stimulation (NPS) technology. Such developments, coupled with the growing incidence of cancer, are likely to boost the market's growth.

However, the high cost of treatment and high susceptibility of basal cell carcinoma to remain underdiagnosed is expected to hinder the market's growth.

Basal Cell Carcinoma Treatment Industry Overview

The basal cell carcinoma treatment market is moderately competitive and consists of several major players. Some of the companies that are currently dominating the market are Merck & Co., Inc., Bausch Health Companies, F. Hoffmann-La Roche Ltd., Mylan N.V., Sun Pharmaceuticals Ltd., Allergan Inc., Perrigo Company Plc., and Strides Arcolab Ltd., among others.

Basal Cell Carcinoma Treatment Market Leaders

  1. Bausch Health Companies Inc.

  2. F. Hoffmann-La Roche AG

  3. Mylan N.V.

  4. Sun Pharmaceuticals Ltd.

  5. Merck & Co. Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Basal Cell Carcinoma Treatment Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Basal Cell Carcinoma Treatment Market News

  • In June 2021, the PD-1 inhibitor Libtayo, developed by Regeneron Pharmaceuticals, Inc., and Sanofi, was authorized by the European Commission (EC) to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).
  • In February 2021, Sanofi's PD-1 inhibitor Libtayo, the first immunotherapy recommended for patients with advanced basal cell carcinoma, received USFDA approval.

Basal Cell Carcinoma Treatment Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Skin Cancers
    • 4.2.2 Increase in Geriatric Population
    • 4.2.3 Environmental Factors Leading to Greater Exposure of UV Radiation
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
    • 4.3.2 High Susceptibility of Basal Cell Carcinoma to remain Under-diagnosed
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Treatment Type
    • 5.1.1 Surgery
    • 5.1.2 Medication
    • 5.1.3 Others
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Specialty Clinics
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie (Allergan)
    • 6.1.2 Bausch Health Companies Inc.
    • 6.1.3 F. Hoffmann-La Roche AG
    • 6.1.4 Medivir AB
    • 6.1.5 Merck & Co. Inc
    • 6.1.6 PellePharm
    • 6.1.7 Perrigo Company plc
    • 6.1.8 Sanofi
    • 6.1.9 Strides Arcolab Ltd
    • 6.1.10 Sun Pharmaceuticals Ltd
    • 6.1.11 Taro Pharmaceutical Industries Ltd
    • 6.1.12 Viatris
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Basal Cell Carcinoma Treatment Industry Segmentation

As per the scope of the report, basal cell carcinoma is a type of skin cancer that begins in the basal cells, which produce new cells when the old ones die. The Basal Cell Carcinoma Treatment market is segmented by Treatment Type (Surgery, Medication, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across the major regions globally. The report offers the value (in USD million) for the above segments.

By Treatment Type Surgery
Medication
Others
By End User Hospitals
Specialty Clinics
Others
Geography North America United States
Canada
Mexico
Geography Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Geography Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Geography Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
Geography South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Basal Cell Carcinoma Treatment Market Research FAQs

What is the current Basal Cell Carcinoma Treatment Market size?

The Basal Cell Carcinoma Treatment Market is projected to register a CAGR of 9.3% during the forecast period (2025-2030)

Who are the key players in Basal Cell Carcinoma Treatment Market?

Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Mylan N.V., Sun Pharmaceuticals Ltd. and Merck & Co. Inc. are the major companies operating in the Basal Cell Carcinoma Treatment Market.

Which is the fastest growing region in Basal Cell Carcinoma Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Basal Cell Carcinoma Treatment Market?

In 2025, the North America accounts for the largest market share in Basal Cell Carcinoma Treatment Market.

What years does this Basal Cell Carcinoma Treatment Market cover?

The report covers the Basal Cell Carcinoma Treatment Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Basal Cell Carcinoma Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Basal Cell Carcinoma Industry Report

Statistics for the 2025 Basal Cell Carcinoma Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Basal Cell Carcinoma Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.